Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
    1.
    发明申请
    Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders 审中-公开
    科蒂他汀和PKC抑制剂治疗肺和心脏疾病

    公开(公告)号:US20080312241A1

    公开(公告)日:2008-12-18

    申请号:US12006825

    申请日:2008-01-03

    摘要: Embodiments of the present invention are related to novel therapeutic drugs, drug combinations, and associated methods for treating or preventing pulmonary disease, including pulmonary hypertension, pulmonary fibrosis, asthma and COPD, and heart failure, together with other pulmonary and cardiovascular diseases and their complications. More particularly, aspects of the present invention are related to the use of cicletanine and ruboxistaurin as monotherapies or in combination with other agents for treatment of disease. Cicletanine may be used as pure (+) or (−) enantiomers or as a racemic or non-racemic mixture of those enantiomers.

    摘要翻译: 本发明的实施方案涉及用于治疗或预防肺部疾病(包括肺动脉高压,肺纤维化,哮喘和COPD)和心力衰竭以及其他肺和心血管疾病及其并发症的新型治疗药物,药物组合和相关方法 。 更具体地,本发明的方面涉及将cicletanine和ruboxistaurin用作单一疗法或与其它药物组合用于治疗疾病。 胞质蛋白可用作纯(+)或( - )对映异构体或作为那些对映体的外消旋或非外消旋混合物。